Phase II trial of gaboxadol [OV101] in patients with fragile X syndrome
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2018
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Acronyms ROCKET
- 11 Jul 2018 According to an Ovid Therapeutics media release, Randi Hagerman is a principal investigator of this trial.
- 11 Jul 2018 Status changed from planning to recruiting, as reported in an Ovid Therapeutics media release.
- 08 May 2018 According to an Ovid Therapeutics media release, company presented three poster presentations, including posters describing the economic and clinical burden of this severe disorder at American Academy of Neurology in April